Global Next Gen Sequencing For Rare Disease Diagnosis Market Companies

Healthcare
Dec 2024
Global
350 Pages
No of Tables: 220
No of Figures: 60

Buy Now

Request for Sample

Nucleus

Companies Covered

Highest Market Share

Dominant Companies

Other Companies

Global Next Gen Sequencing For Rare Disease Diagnosis Market Share Analysis

The data presented is for visualization purposes only and may not reflect actual results.

Nucleus : Company Analysis Platform

Request for Demo >

Frequently Asked Questions

What are the primary segments covered in the Global Next Gen Sequencing For Rare Disease Diagnosis Market report?

The market is segmented based on Global Next-Gen Sequencing for Rare Disease Diagnosis Market Segmentation, By Product Type (Reagents & Consumables, Instruments, and Software), Technology (Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), and Targeted Sequencing, RNA Sequencing), Application (Rare Genetic Diseases, Cancer, Neurological Disorders, and Infectious Diseases), End-User (Hospitals, Diagnostic Laboratories, Research Institutes, and Pharmaceutical & Biotech Companies) – Industry Trends and Forecast to 2032 .

What is the current market size of the Global Next Gen Sequencing For Rare Disease Diagnosis Market?

The Global Next Gen Sequencing For Rare Disease Diagnosis Market size was valued at USD 1.44 USD Million in 2024.

What is the expected growth rate of the Global Next Gen Sequencing For Rare Disease Diagnosis Market?

The Global Next Gen Sequencing For Rare Disease Diagnosis Market is projected to grow at a CAGR of 8.1% during the forecast period of 2025 to 2032.

Who are the key players in the Global Next Gen Sequencing For Rare Disease Diagnosis Market?

The major players operating in the market include IlluminaInc. , Thermo Fisher Scientific Inc. , Pacific Biosciences , Oxford Nanopore Technologies , BGI Genomics AGilent TechnologiesInc. , F. Hoffmann-La Roche Ltd. , PerkinElmerInc. , OPKO Health , Twist Bioscience , Bio-Rad LaboratoriesInc. , QIAgen N.V. , Mammoth Biosciences , New England BiolabsInc. , SomaLogicInc. , and Nanostring TechnologiesInc. ..

Which countries are analyzed in the Global Next Gen Sequencing For Rare Disease Diagnosis Market report?

The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.